Akebia Therapeutics Statistics
Total Valuation
AKBA has a market cap or net worth of $372.35 million. The enterprise value is $384.95 million.
Important Dates
The last earnings date was Thursday, February 26, 2026, before market open.
| Earnings Date | Feb 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AKBA has 267.88 million shares outstanding. The number of shares has increased by 21.91% in one year.
| Current Share Class | 267.88M |
| Shares Outstanding | 267.88M |
| Shares Change (YoY) | +21.91% |
| Shares Change (QoQ) | -3.28% |
| Owned by Insiders (%) | 2.09% |
| Owned by Institutions (%) | 46.91% |
| Float | 262.27M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.57 |
| Forward PS | 1.33 |
| PB Ratio | 11.23 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 5.48 |
| P/OCF Ratio | 5.46 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 14.11, with an EV/FCF ratio of 5.69.
| EV / Earnings | n/a |
| EV / Sales | 1.63 |
| EV / EBITDA | 14.11 |
| EV / EBIT | 14.80 |
| EV / FCF | 5.69 |
Financial Position
The company has a current ratio of 1.55, with a Debt / Equity ratio of 6.10.
| Current Ratio | 1.55 |
| Quick Ratio | 1.42 |
| Debt / Equity | 6.10 |
| Debt / EBITDA | 6.16 |
| Debt / FCF | 2.94 |
| Interest Coverage | 1.08 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 5.44% |
| Return on Invested Capital (ROIC) | 8.76% |
| Return on Capital Employed (ROCE) | 12.17% |
| Weighted Average Cost of Capital (WACC) | 7.57% |
| Revenue Per Employee | $1.22M |
| Profits Per Employee | -$27,552 |
| Employee Count | 194 |
| Asset Turnover | 0.79 |
| Inventory Turnover | 2.53 |
Taxes
In the past 12 months, AKBA has paid $1.62 million in taxes.
| Income Tax | 1.62M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.54% in the last 52 weeks. The beta is 0.40, so AKBA's price volatility has been lower than the market average.
| Beta (5Y) | 0.40 |
| 52-Week Price Change | -25.54% |
| 50-Day Moving Average | 1.38 |
| 200-Day Moving Average | 2.49 |
| Relative Strength Index (RSI) | 55.39 |
| Average Volume (20 Days) | 3,428,792 |
Short Selling Information
The latest short interest is 31.21 million, so 11.65% of the outstanding shares have been sold short.
| Short Interest | 31.21M |
| Short Previous Month | 36.93M |
| Short % of Shares Out | 11.65% |
| Short % of Float | 11.90% |
| Short Ratio (days to cover) | 8.89 |
Income Statement
In the last 12 months, AKBA had revenue of $236.20 million and -$5.35 million in losses. Loss per share was -$0.02.
| Revenue | 236.20M |
| Gross Profit | 195.84M |
| Operating Income | 26.00M |
| Pretax Income | -3.72M |
| Net Income | -5.35M |
| EBITDA | 27.27M |
| EBIT | 26.00M |
| Loss Per Share | -$0.02 |
Full Income StatementBalance Sheet
The company has $184.84 million in cash and $198.78 million in debt, with a net cash position of -$13.94 million or -$0.05 per share.
| Cash & Cash Equivalents | 184.84M |
| Total Debt | 198.78M |
| Net Cash | -13.94M |
| Net Cash Per Share | -$0.05 |
| Equity (Book Value) | 32.61M |
| Book Value Per Share | 0.12 |
| Working Capital | 90.02M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $67.99 million and capital expenditures -$291,000, giving a free cash flow of $67.70 million.
| Operating Cash Flow | 67.99M |
| Capital Expenditures | -291,000 |
| Free Cash Flow | 67.70M |
| FCF Per Share | $0.25 |
Full Cash Flow StatementMargins
Gross margin is 82.92%, with operating and profit margins of 11.01% and -2.26%.
| Gross Margin | 82.92% |
| Operating Margin | 11.01% |
| Pretax Margin | -1.58% |
| Profit Margin | -2.26% |
| EBITDA Margin | 11.55% |
| EBIT Margin | 11.01% |
| FCF Margin | 28.66% |
Dividends & Yields
AKBA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -21.91% |
| Shareholder Yield | -21.91% |
| Earnings Yield | -1.44% |
| FCF Yield | 18.25% |
Analyst Forecast
The average price target for AKBA is $5.75, which is 313.67% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $5.75 |
| Price Target Difference | 313.67% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 12.86% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AKBA has an Altman Z-Score of -3.97 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.97 |
| Piotroski F-Score | 5 |
